The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Commentary|Articles|June 2, 2026
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
Author(s)Jennifer Eads, MD
Fact checked by: Chris Ryan, Ashling Wahner
Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.
Advertisement
Jennifer Eads, MD, a professor of clinical medicine (hematology-oncology), physician lead for Gastrointestinal (GI) Clinical Research, and director of the National Clinical Trials Network at Abramson Cancer Center of the University of Pennsylvania, discussed early data from a phase 1/2 trial (NCT06055439) evaluating the CDH17-directed CAR T-cell therapy CHM-2101 for the treatment of patients with relapsed/refractory GI cancers.
Advertisement
Related to this article
The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
The zanidatamab-plus-chemotherapy arm met its overall survival end point at the second interim analysis of the phase 3 HERIZON-GEA-01 trial.
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5